VIDEO: Oral Stargardt’s disease treatment focuses on reducing vitamin A dimerization

CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Michel Dahan, CEO of Alkeus Pharmaceuticals discusses ALK-001, the company’s oral therapy for the treatment of Stargardt’s disease and age-related macular degeneration.

ALK-001 (gildeuretinol) is “a new chemical entity designed to lower dimerization in the retina and do so without modulating the visual cycle,” he said.

Dahan also discussed a trial investigating the oral treatment for geographic atrophy.

Published by:

Read more about

This post was originally published on this site